Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Churchill Capital Corp XI - Class A Ordinary Shares (NQ:CCXI)

10.29 UNCHANGED
Streaming Delayed Price Updated: 3:53 PM EDT, Apr 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Churchill Capital Corp XI - Class A Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Two Down With Sanofi Bowing Out From Horizon Buyout Talks, Amgen Agrees To Buy For $116.5/Share ↗
 
Via Benzinga
News headline image
How to Trade the High-Growth Biotech Sector in the Midst of a Bear Market ↗
Biotech is an exciting and emerging space that’s attracted increasing investor interest in recent years. 
Via Benzinga
News headline image
ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings
From ChemoCentryx, Inc.
Via GlobeNewswire
News headline image
Biotech Stocks Well-Positioned For The Fourth Quarter ↗
The path of interest rates is clearer for 2022 and the FED is closer to a pause early next year as it calibrates its response from a hammer approach so far. 
Via Talk Markets
News headline image
ChemoCentryx: Q2 Earnings Insights ↗
  ChemoCentryx (NASDAQ:CCXI) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:05 PM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
3 Analysts Have This to Say About ChemoCentryx ↗
ChemoCentryx (NASDAQ:CCXI) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
ChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting
From ChemoCentryx, Inc.
Via GlobeNewswire
News headline image
These Were the Five Best And Worst Performing Mid-Cap Stocks In August 2022 ↗
We have used the August return data from finviz.com to come up with the five best and worst performing mid-cap stocks in August 2022. 
Via Talk Markets
News headline image
Here Are 10 Biotech Stocks — Including Catalyst And Viridian — That Would Have Netted You $10,000 More This Year ↗
The biotech run off a June bottom is great — until you realize you could've netted more. 
Via Investor's Business Daily
News headline image
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin ↗
The market is struggling, yet biotech stocks are acting like it's good times again. Here's why. 
Via Investor's Business Daily
News headline image
INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates ChemoCentryx, Inc.’s Directors and Officers for Breach of Fiduciary Duties – CCXI
From Scott+Scott Attorneys at Law LLP
Via Business Wire
News headline image
7 Dow Stocks With Superior Fundamentals ↗
Robust Dow stocks offer attractive deals for patient investors amidst an unstable economic environment 
Via InvestorPlace
News headline image
Healthcare Sector Still Looks Good But Lacks Momentum ↗
The summer rally is over it’s a holiday weekend with low trading volume and bad news is pervasive. A decent jobs report on Friday brought in buyers in early hours until Russia intervened with a Nord... 
Via Talk Markets
News headline image
ChemoCentryx's Return On Capital Employed Insights ↗
According to data from Benzinga Pro, during Q2, ChemoCentryx's (NASDAQ:CCXI) reported sales totaled $11.76 million. Despite a 18.02% increase in earnings, the company posted a loss of $31.65 million. 
Via Benzinga
News headline image
INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates ChemoCentryx, Inc.’s Directors and Officers for Breach of Fiduciary Duties – CCXI
From Scott+Scott Attorneys at Law LLP
Via Business Wire
News headline image
10 Biotech Stocks Are Up 40% Or More This Year, Including Karuna, Axsome And Others ↗
These names are benefitting from M&A, clinical data and promising regulatory actions. 
Via Investor's Business Daily
News headline image
Whither Small Caps After Fed’s Tough Talk? ↗
For now its better not to “Fight the Fed” because they are fighting the with the market. Now that everyone is scared of the Fed's rhetoric it would be better to wait a week or so as more data and... 
Via Talk Markets
News headline image
Blistering-Hot Biotech Shopping Spree Continues: Alcon To Buy Aerie For $770 Million ↗
The biopharma buying spree continued Tuesday with glaucoma drugs maker Aerie. 
Via Investor's Business Daily
News headline image
Check your Portfolio for Small Cap Weighting: Growth, Innovation or Speculation? ↗
The SPDR S&P Biotech ETF remains our key indicator for small cap biotechs. It is up 14.55% over one month at $93.78 but is still down 16% YTD. The Russell 2000 is up 16.5% over one month mirroring... 
Via Talk Markets
News headline image
Why Jim Cramer Says This Financial Stock Is 'Terrific' ↗
On CNBC’s "Mad Money Lightning Round," Jim Cramer said The Charles Schwab Corporation (NYSE: SCHW) is "terrific." 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2022 ↗
  
Via Benzinga
News headline image
Earnings Preview: ChemoCentryx ↗
  ChemoCentryx (NASDAQ:CCXI) is set to give its latest quarterly earnings report on Tuesday, 2022-08-09. Here's what investors need to know before the announcement. Analysts estimate that ChemoCentryx... 
Via Benzinga
News headline image
Small Cap Biotechs Perk Up On Dealmaking ↗
With M&A picking up we would think smaller deals make sense for large cap biopharma to expand pipelines and complement technology. 
Via Talk Markets
News headline image
Stock Market Rally Mixed As Oil Prices Fall, Job Growth Hot: Weekly Review ↗
The Nasdaq and small caps rose while the S&P 500 is hitting resistance. 
Via Investor's Business Daily
News headline image
Where ChemoCentryx Stands With Analysts ↗
Over the past 3 months, 4 analysts have published their opinion on ChemoCentryx (NASDAQ:CCXI) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Coinbase, MercadoLibre And Some Other Big Stocks Recording Gains On Thursday ↗
U.S. stocks closed mixed on Thursday following the release of weekly jobless claims data. Here is the list of some big stocks moving higher in the previous session. 
Via Benzinga
News headline image
Why NanoViricides Jumped Over 48%; Here Are 106 Biggest Movers From Yesterday ↗
Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) surged 109.2% to settle at $50.43 on Thursday after the company, and Amgen, announced an agreement under which Amgen will acquire the company for $52 per share... 
Via Benzinga
News headline image
Amgen Narrows Sales Outlook Following Plans To Acquire ChemoCentryx ↗
The company also reported a second-quarter beat and reiterated its earnings outlook. 
Via Investor's Business Daily
News headline image
Gold Tops 1,800; Alibaba Reports Upbeat Results ↗
U.S. stocks traded mixed toward the end of trading, with the Dow Jones dropping around 75 points on Thursday 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.